AIM Platform: Generates Highly Specific CD8+ T Cell Products with Significant Anti-tumor Functionality

Sojung Kim1, Lauren Suarez1, Emily Lu1, Celine Walmacq1, Daniel Dembrow1, Daniel Bednárik1, Kristi Jones1, Naimish Pandya1, Juan Varela1, Tatsuya Yoshida1, Jeffrey S Weber1, Mathias Oelke1

NexImmune, Inc., Gaithersburg, MD; Florida Hospital Cancer Institute, Orlando, FL; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY

BACKGROUND

- Single tumor antigen recognition via a genetically modified CD4+ or CD8+ T cell in combination with a truly individualized approach for targeting malignant cells
- Antigen-specific Endogenous T-Cell Therapy (ETT) offers a non-genetically modified approach to generate T cells targeting multiple tumor antigens in a single cellular product
- Current ETT technologies depend upon antigen-specific generating cells to activate and expand antigen-specific T cells
- The AIM™ platform uses nanoparticle-based artificial Antigen Presenting Cells (aAPCs) that are a mixture of lymphocytes (CD8+ CD57+ Eff. T cells)
- Clinical experience demonstrates both meaningful lead and sizable response

AIM Platform: Generates Highly Specific CD8+ T Cell Products using nanoparticle-based artificial Antigen Presenting Cells (aAPCs)

- Our proprietary approach leads to direct expansion of naturally selected CD8+ T cells without requiring antigen processing and presentation by them
- aAPCs are designed to drive specific targeting of CD8- T cell receptors on both naive bystander T cells and antigen-selected immune responses
- Antigen-specific CD8+ T cells are highly antigen-specific, highly polyfunctional, and composed of high proportions of memory and effector T cells from donors

EXPLORATORY DATA FOR OTHER THERAPEUTIC INDICATIONS

MULTIPLE MYELOMA

- AML Antigen-Specific T Cells (Day 14)
- Phenotype of final cellular product after E+E (Day 14)
- Number of Cytokines
- CD62L
- CD62L
- CD107a

TH1 MANUFACTURING DELIVERS CONSISTENT T CELL CHARACTERISTICS ACROSS INDICATIONS AND LOTS

- E+E generates sufficient multi-target Cell Numbers to Deliver Minimum Dose

SUMMARY

- The AIM ACT cellular product:
  - In-composed of a multi-antigen specific, CD8+ enriched, T cells from an individualized repertoire
  - Contains a range from 2% up to 99% of antigen-specific CD8+ T cells

- T-cell functionality
  - Robust killing activity demonstrated across multiple E:T ratios
  - % Multimer Positive T Cells
  - % Viability

- E+F- consistently produces clinical results regardless of source material

- AIM ACT Phase 1 clinical trials targeting AML and Multiple Myeloma are planned for 2H 2019


http://neximmune.com/